New regulations on pharmaceutical credit evaluation will be issued: comprehensive and strict, dishonest pharmaceutical companies must reduce prices for "rectification"
2025-05-26 03:06:39
On May 26th, the five-year-old pharmaceutical price and procurement via bidding credit evaluation system is about to usher in major revisions, and will urge untrustworthy enterprises to correct their untrustworthy behavior by actively reducing prices and "squeezing water". The reporter learned from relevant sources that the National Medical Insurance Bureau will release the revised new version of the pharmaceutical price and procurement via bidding credit evaluation system in the near future, including the 2025 version of the list of medical prices and procurement via bidding untrustworthy matters and the operation specifications for credit evaluation. Deng Yong, director of the Research and Innovation Transformation Center for Health and Rule of Law at Beijing University of Traditional Chinese Medicine, said that by establishing a credit evaluation system, linking illegal acts identified by legal judgments and administrative penalties to corporate credit, the formation of market rules of "dishonesty must be punished and trustworthy benefits" will be promoted, forcing enterprises to operate in a standardized manner.
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
